FibroGen (FGEN) Announces Receipt of $120M Milestone from AstraZeneca (AZN)
Tweet Send to a Friend
FibroGen (NASDAQ: FGEN) has received a scheduled $120.0 million non-contingent license payment from AstraZeneca AB ("AstraZeneca") under its collaboration agreements ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE